JP2007502313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007502313A5 JP2007502313A5 JP2006529794A JP2006529794A JP2007502313A5 JP 2007502313 A5 JP2007502313 A5 JP 2007502313A5 JP 2006529794 A JP2006529794 A JP 2006529794A JP 2006529794 A JP2006529794 A JP 2006529794A JP 2007502313 A5 JP2007502313 A5 JP 2007502313A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- optionally substituted
- group
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 229910052739 hydrogen Inorganic materials 0.000 claims 39
- 239000001257 hydrogen Substances 0.000 claims 39
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 22
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 15
- -1 cyano, phenyl Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 7
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 5
- 229950010035 davercin Drugs 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 150000001540 azides Chemical class 0.000 claims 4
- 229960004099 azithromycin Drugs 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 2
- 125000003302 alkenyloxy group Chemical group 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 229960003276 erythromycin Drugs 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000000813 microbial effect Effects 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 229910052717 sulfur Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0310986.5A GB0310986D0 (en) | 2003-05-13 | 2003-05-13 | Novel compounds |
| PCT/EP2004/005082 WO2004101586A1 (en) | 2003-05-13 | 2004-05-11 | Novel 14 and 15 membered-ring compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007502313A JP2007502313A (ja) | 2007-02-08 |
| JP2007502313A5 true JP2007502313A5 (enExample) | 2007-06-28 |
Family
ID=9957984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006529794A Pending JP2007502313A (ja) | 2003-05-13 | 2004-05-11 | 新規１４及び１５員環化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7569550B2 (enExample) |
| EP (1) | EP1628988B1 (enExample) |
| JP (1) | JP2007502313A (enExample) |
| KR (1) | KR20060026407A (enExample) |
| CN (1) | CN1849328A (enExample) |
| AR (1) | AR044309A1 (enExample) |
| AT (1) | ATE341560T1 (enExample) |
| AU (1) | AU2004238528A1 (enExample) |
| BR (1) | BRPI0410246A (enExample) |
| CA (1) | CA2525452A1 (enExample) |
| CL (1) | CL2004001010A1 (enExample) |
| DE (1) | DE602004002696T2 (enExample) |
| DK (1) | DK1628988T3 (enExample) |
| ES (1) | ES2273255T3 (enExample) |
| GB (1) | GB0310986D0 (enExample) |
| HR (1) | HRP20060448T3 (enExample) |
| MX (1) | MXPA05012163A (enExample) |
| PL (1) | PL1628988T3 (enExample) |
| PT (1) | PT1628988E (enExample) |
| RU (1) | RU2005134908A (enExample) |
| WO (1) | WO2004101586A1 (enExample) |
| ZA (1) | ZA200509079B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0424961D0 (en) * | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| GB0424958D0 (en) * | 2004-11-11 | 2004-12-15 | Glaxo Group Ltd | Novel compounds |
| EP1851236B1 (en) * | 2005-01-13 | 2010-08-04 | GlaxoSmithKline istrazivacki centar Zagreb d.o.o. | Macrolides with anti-inflammatory activity |
| WO2006120541A1 (en) * | 2005-05-10 | 2006-11-16 | Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. | Ether linked macrolides useful for the treatment of microbial infections |
| PE20070802A1 (es) * | 2005-11-09 | 2007-10-19 | Glaxo Group Ltd | Derivados de eritromicina 4''-sustituidos como agentes antimicrobianos |
| EP1945652A1 (en) * | 2005-11-09 | 2008-07-23 | Glaxo Group Limited | Macrolones |
| EP2384333B1 (en) | 2009-01-30 | 2013-04-17 | Glaxo Group Limited | Anti-inflammatory macrolide |
| CN111574575B (zh) * | 2020-04-29 | 2022-05-17 | 北京理工大学 | 一种含有大环内酯基的喹喏酮衍生物、制备方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE128714T1 (de) * | 1989-03-28 | 1995-10-15 | Abbott Lab | Erythromycinderivate. |
| WO1996034007A1 (es) * | 1995-04-27 | 1996-10-31 | Laboratorios Aranda, S.A. De C.V. | Derivados de quinolonilcarboxieritromicina y composiciones farmaceuticas que los contienen |
| CA2253451A1 (en) * | 1996-05-07 | 1997-11-13 | Abbott Laboratories | 3-descladinose-2,3-anhydroerythromycin derivatives |
| GB0025688D0 (en) * | 2000-10-19 | 2000-12-06 | Glaxo Group Ltd | Macrolides |
| WO2003014136A1 (en) * | 2001-08-08 | 2003-02-20 | Taisho Pharmaceutical Co., Ltd. | 11a-AZALIDE COMPOUNDS AND PROCESS FOR PRODUCING THE SAME |
| GB0127349D0 (en) * | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
-
2003
- 2003-05-13 GB GBGB0310986.5A patent/GB0310986D0/en not_active Ceased
-
2004
- 2004-05-11 RU RU2005134908/04A patent/RU2005134908A/ru not_active Application Discontinuation
- 2004-05-11 CL CL200401010A patent/CL2004001010A1/es unknown
- 2004-05-11 AT AT04732102T patent/ATE341560T1/de not_active IP Right Cessation
- 2004-05-11 HR HR20060448T patent/HRP20060448T3/xx unknown
- 2004-05-11 BR BRPI0410246-0A patent/BRPI0410246A/pt not_active IP Right Cessation
- 2004-05-11 DE DE602004002696T patent/DE602004002696T2/de not_active Expired - Lifetime
- 2004-05-11 CA CA002525452A patent/CA2525452A1/en not_active Abandoned
- 2004-05-11 US US10/556,645 patent/US7569550B2/en not_active Expired - Fee Related
- 2004-05-11 PL PL04732102T patent/PL1628988T3/pl unknown
- 2004-05-11 EP EP04732102A patent/EP1628988B1/en not_active Expired - Lifetime
- 2004-05-11 JP JP2006529794A patent/JP2007502313A/ja active Pending
- 2004-05-11 PT PT04732102T patent/PT1628988E/pt unknown
- 2004-05-11 AU AU2004238528A patent/AU2004238528A1/en not_active Abandoned
- 2004-05-11 DK DK04732102T patent/DK1628988T3/da active
- 2004-05-11 CN CNA2004800192646A patent/CN1849328A/zh active Pending
- 2004-05-11 AR ARP040101614A patent/AR044309A1/es not_active Application Discontinuation
- 2004-05-11 KR KR1020057021593A patent/KR20060026407A/ko not_active Withdrawn
- 2004-05-11 WO PCT/EP2004/005082 patent/WO2004101586A1/en not_active Ceased
- 2004-05-11 ES ES04732102T patent/ES2273255T3/es not_active Expired - Lifetime
- 2004-05-11 MX MXPA05012163A patent/MXPA05012163A/es active IP Right Grant
-
2005
- 2005-11-09 ZA ZA200509079A patent/ZA200509079B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023201821B2 (en) | Modulators of the integrated stress pathway | |
| EP2643323B1 (en) | Compounds for treating respiratory syncytial virus infections | |
| JP6005656B2 (ja) | ベンゾイミダゾール呼吸合胞体ウイルス阻害剤 | |
| PT656778E (pt) | Nucleosidos de beta-d-dioxolano sob a forma de enantiomeros puros | |
| JP2006523193A5 (enExample) | ||
| JP2005519932A5 (enExample) | ||
| MXPA06007109A (es) | Derivados de piperidina-amino-bencimidazol como inhibidores de la replicacion del virus sincitial respiratorio. | |
| AU2013276520A1 (en) | 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents | |
| JP2004517070A5 (enExample) | ||
| JP2008519788A5 (enExample) | ||
| JP2006523192A5 (enExample) | ||
| KR20140045413A (ko) | 리팍시민의 다형체 및 그의 제조방법 | |
| JP2006528667A5 (enExample) | ||
| JP2007502313A5 (enExample) | ||
| TWI356055B (en) | Aminobenzimidazoles and benzimidazoles as inhibito | |
| RU2007121581A (ru) | Макролоны-аминозамещенные хинолоны | |
| JP2004523478A5 (enExample) | ||
| JP2007532628A5 (enExample) | ||
| JP2004529172A5 (enExample) | ||
| JP2012500249A5 (enExample) | ||
| RU2006143051A (ru) | Сложноэфирные производные макролидов, применение для лечения микробных инфекций | |
| JP2006528947A5 (enExample) | ||
| JP2004534758A5 (enExample) | ||
| EP1896473A1 (en) | 1- ( 2-amino-3- (substituted alkyl)-3h-benzimidazoiylmethyl) -3-subtituted-1,3-dihydro-benzoimidazol-2-ones with activity on respiratory syncytial virus | |
| RU2005134908A (ru) | Новые соединения с 14- и 15-членными кольцами |